Recipharm announces cost and efficiency program in Sweden

In the Swedish part of the Business Segment Solids and Others, there is need to
adapt to lower actual and forecasted volumes of certain products and capture
opportunities for improved efficiency. Therefore, accelerated cost and
efficiency activities will start during Q4 2015 and run through 2016. The
activities will improve margins. Regrettably these activities will affect the
number of employees.
Recipharm is today announcing that around 100 positions in greater Stockholm
area are subject to notice. The ambition is to achieve annual savings in excess
of SEK 60 million from headcount reductions as well as savings in external
costs. There will also be efficiencies to gain from streamlining the product
range and termination of less profitable contracts. Implementation costs of SEK
15 million are expected and will be charged to Q4 2015 results. Savings are
expected to start impact results already in Q1 2016 with full effect beginning
of 2017.

The headcount reductions are subject to negotiations with unions.

Progress updates on the program will be included in Recipharm’s earnings
reports.

For more information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 00
Björn Westberg, CFO, ir@recipharm.com, telephone: +46 8 602 52 00

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ Stockholm. This information was submitted for publication on 8 October
2015, at 14:00 hrs CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 2,200 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage
forms, production of clinical trial material including API and pharmaceutical
product development. Recipharm manufactures more than 400 different products to
customers ranging from Big Pharma to smaller research- and development
companies. Recipharm’s turnover is approximately SEK 3.3 billion and the Company
operates development and manufacturing facilities in Sweden, France, the UK,
Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The
Recipharm B-share (RECI B) is listed on NASDAQ Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com